Apriso is owned by Valeant Pharms Intl.
Apriso contains Mesalamine.
Apriso has a total of 1 drug patent out of which 0 drug patents have expired.
Apriso was authorised for market use on 31 October, 2008.
Apriso is available in capsule, extended release;oral dosage forms.
Apriso can be used as for the maintenance of remission of ulcerative colitis.
The generics of Apriso are possible to be released after 01 May, 2030.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8865688 | VALEANT PHARMS INTL | Compositions and methods for treatment of bowel diseases with granulated mesalamine |
May, 2030
(7 years from now) |
Drugs and Companies using MESALAMINE ingredient
Market Authorisation Date: 31 October, 2008
Treatment: For the maintenance of remission of ulcerative colitis
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic